Solta Medical Inc  

(Public, NASDAQ:SLTM)   Watch this stock  
Find more results for SLTM
2.15
+0.02 (0.94%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.10 - 2.18
52 week 1.44 - 3.53
Open 2.12
Vol / Avg. 427,348.00/451,721.00
Mkt cap 170.58M
P/E     -
Div/yield     -
EPS -0.51
Shares 79.34M
Beta 2.55
Inst. own 53%
Jul 22, 2013
Q2 2013 Solta Medical, Inc. Earnings Release Add to calendar
Jun 5, 2013
Solta Medical, Inc. Annual Shareholder Meeting - 12:00PM EDT - Add to calendar
May 1, 2013
Q1 2013 Solta Medical, Inc. Earnings Conference Call - Webcast
May 1, 2013
Q1 2013 Solta Medical, Inc. Earnings Release
Mar 18, 2013
Solta Medical, Inc. at Roth Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -7.52% -26.29%
Operating margin -5.04% -24.75%
EBITD margin - 5.95%
Return on average assets -4.34% -17.31%
Return on average equity -8.70% -32.17%
Employees 371 -
Carbon Disclosure Rating - -

Address

25881 Industrial Boulevard
HAYWARD, CA 94545
United States - Map
+1-510-7822286 (Phone)
+1-510-7866895 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company's systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets. The Company�s portfolio of products includes six brands that are primarily designed for aesthetic applications: The Fraxel re:pair system provides ablative laser skin resurfacing while the non-ablative Fraxel platform and Clear + Brilliant systems provide treatment for skin rejuvenation. The Thermage system provides non-invasive skin tightening and the Liposonix system provides non-invasive body contouring. Isolaz and CLARO provide both professional and consumer treatment options to resolve acne. In February 2013, the Company acquired Sound Surgical Technologies.

Officers and directors

Stephen J. Fanning Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
John F. Glenn Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
H. Daniel Ferrari Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Doug W Heigel Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Jeff C. Nardoci Vice President - Global Marketing
Age: 51
Bio & Compensation  - Reuters
Lisa Parr Vice President - Regulatory Affairs and Clinical Affairs
Bio & Compensation  - Reuters
Thomas J. Yorkey Ph.D. Vice President - Research & Development
Age: 50
Bio & Compensation  - Reuters
Mark M. Sieczkarek Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
David B. Holthe CPA Director
Bio & Compensation  - Reuters
Harold L. Covert Independent Director
Age: 66
Bio & Compensation  - Reuters